Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | RYR1 | P21817 | 7/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.35 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 4/20 | 0.30 |
| ▸ | ACE | P12821 | 4/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184127 | 0.79 | CRBN (0.38) | CRBNFKBP5OR51E2RYR1FKBP1A | |
| SCHEMBL5105763 | 0.73 | OR51E2 (0.36) | CRBNFKBP5OR51E2RYR1FKBP1A | |
| 2-Pyrrolidone SCHEMBL9100871 | 0.72 | OR51E2 (0.71) | CRBNFKBP5OR51E2 | |
| SCHEMBL10764833 | 0.72 | — | — | |
| SCHEMBL31557611 | 0.65 | TSHR (0.38) | MMEACEECE1 | |
| SCHEMBL31557612 | 0.65 | TSHR (0.38) | MMEACEECE1 | |
| SCHEMBL18425184 | 0.65 | TRIM24 (0.38) | BMPR2MMEACEECE1 | |
| SCHEMBL18396750 | 0.65 | — | — | |
| SCHEMBL25430542 | 0.63 | CRBN (0.94) | CRBNFKBP5OR51E2 | |
| SCHEMBL14811593 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | BACE1, BACE2, APP | CRBN 1100/4885FKBP5 3581/4885OR51E2 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.